Catalyst Event
Eli Lilly and Co (LLY) · Other
From KEDI Global Obesity Care Industry Top 2+ Index (OBCI)
3/19/2026, 12:00:00 AM
Announced positive topline results from the Phase 3 trial of retatrutide for type 2 diabetes, showing significant reductions in both blood sugar and weight.
Korean Translation
제2형 당뇨병 치료제 레타트루타이드(retatrutide)의 3상 임상시험에서 혈당과 체중 모두에서 유의미한 감소를 보인 긍정적인 탑라인 결과를 발표함.
Related Recent Events
Eli Lilly and Co (LLY) · Earnings Release
Q1 2026 earnings release scheduled. Analysts forecast EPS around $7.25-$7.50 estimated. High importance estimated due to the significant weight of earnings reports on stock volatility.
4/30/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Other
Expected FDA decision date for oral obesity drug orforglipron scheduled. High importance estimated as FDA decisions for major drugs typically cause >10% price swings.
4/10/2026, 12:00:00 AM
DICK'S Sporting Goods Inc (DKS) · Other
The ex-dividend date for the quarterly cash dividend of $1.25 per share is March 27, 2026, representing a 3% increase over the previous quarterly dividend.
3/27/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Other
Annual General Meeting 2026 scheduled.
3/26/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Other
HSBC downgraded the stock from 'Hold' to 'Reduce' with a price target of $850, citing valuation concerns and competitive pressures.
3/22/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Other
Patents for semaglutide, the active ingredient in Ozempic and Wegovy, expired in key markets including China and India. This event opens the door to generic competition in those regions.
3/20/2026, 12:00:00 AM